Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 18/20 | 1.00 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 1.00 |
| ▸ | BPTF | Q12830 | 2/20 | 1.00 |
| ▸ | KAT2A | Q92830 | 2/20 | 1.00 |
| ▸ | BRD1 | O95696 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | BRPF1 | P55201 | 1/20 | 1.00 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 1.00 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 1.00 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 1.00 |
| ▸ | SETDB1 | Q15047 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23682853 | 1.00 | KAT2B (1.00) | KAT2BBRD9BPTFKAT2ABRD1 | |
| SCHEMBL26216685 | 1.00 | KAT2B (1.00) | KAT2BBRD9BPTFKAT2ABRD1 | |
| SCHEMBL30830559 | 0.89 | KAT2B (0.79) | KAT2BBRD9BPTFKAT2ABRD1 | |
| SCHEMBL25445787 | 0.87 | KAT2B (0.77) | KAT2BBRD9BPTFKAT2ABRD1 | |
| SCHEMBL30830606 | 0.87 | KAT2B (0.77) | KAT2BBRD9BPTFKAT2ABRD1 | |
| SCHEMBL26547075 | 0.87 | KAT2B (0.77) | KAT2BBRD9BPTFKAT2ABRD1 | |
| SCHEMBL23682875 | 0.87 | KAT2B (1.00) | KAT2BBRD9BPTFKAT2ABRD1 | |
| SCHEMBL17916738 | 0.87 | KAT2B (1.00) | KAT2BBRD9BPTFKAT2ABRD1 | |
| SCHEMBL17912355 | 0.87 | KAT2B (1.00) | KAT2BBRD9BPTFKAT2ABRD1 | |
| SCHEMBL23718084 | 0.87 | KAT2B (1.00) | KAT2BBRD9BPTFKAT2ABRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2025-10-02 | — | — | US | disclosed |
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| EP-4540249-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | Yeda Research and Development Co. Ltd (IL) | 2025-04-23 | — | — | EP | disclosed |
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | FLAGSHIP PIONEERING, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20240424098-A1 | MODIFIED IMMUNE CELLS AND METHODS OF USE THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2024-12-26 | — | — | US | disclosed |
| WO-2024220843-A1 | TECHNOLOGIES TARGETING CELL STATES | AURON THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| EP-4412626-A1 | MODIFIED IMMUNE CELLS AND METHODS OF USE THEREOF | University Health Network (CA) | 2024-08-14 | — | — | EP | disclosed |
| US-20240139326-A1 | METHACRYLAMIDES PROTEIN BINDERS AND USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-05-02 | — | — | US | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| WO-2023242845-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (CoLDR) COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-12-21 | — | — | WO | disclosed |
| CN-111909108-B | Biphenyl compound and preparation method and medical application thereof | 中国药科大学 | 2023-05-02 | — | — | CN | disclosed |
| WO-2023057931-A1 | MODIFIED IMMUNE CELLS AND METHODS OF USE THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2023-04-13 | — | — | WO | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| EP-4133059-A1 | COMPOSITIONS AND METHODS FOR ENHANCING ACTIVATION AND CYTOLYTIC ACTIVITY OF CD8+T CELLS THROUGH DISRUPTION OF THE SAGA (SPT-ADA-GCN5-ACETYLTRANSFERASE) COMPLEX | University Health Network (CA) | 2023-02-15 | — | — | EP | disclosed |
| CN-115461452-A | Compositions and methods for enhancing activation and cytolytic activity of CD8+ T cells by disrupting SAGA (Spt-Ada-Gcn 5-acetyltransferase) complex | 大学健康网络 | 2022-12-09 | — | — | CN | disclosed |
| WO-2022076735-A1 | INHIBITORS OF THE BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR (BPTF) AS ANTI-CANCER AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | KAT2B 36/4885BRD9 2265/4885BPTF 1130/4885 |
| US-20240139326-A1 | METHACRYLAMIDES PROTEIN BINDERS AND USES THEREOF | STAMBP, HSPBP1, ECPAS | KAT2B 2289/4885BRD9 220/4885BPTF 1778/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | KAT2B 2513/4885BRD9 2024/4885BPTF 166/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | KAT2B 645/4885BRD9 4029/4885BPTF 3457/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | KAT2B 735/4885BRD9 3664/4885BPTF 104/4885 |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | CASR, NPSR1, GSR | KAT2B 2365/4885BRD9 1055/4885BPTF 1940/4885 |
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | EFTUD2, DDX21, SNRPE | KAT2B 3350/4885BRD9 3375/4885BPTF 742/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | KAT2B 1273/4885BRD9 472/4885BPTF 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.